Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas

BACKGROUND: The “HER2-low” nomenclature identifies breast carcinomas (BCs) displaying a HER2 score of 1+/2+ in immunohistochemistry and lacking ERBB2 amplification. Whether HER2-low BCs (HLBCs) constitute a distinct entity is debated. METHODS: We performed DNA and RNA high-throughput analysis on 99...

Descripción completa

Detalles Bibliográficos
Autores principales: Berrino, Enrico, Annaratone, Laura, Bellomo, Sara Erika, Ferrero, Giulio, Gagliardi, Amedeo, Bragoni, Alberto, Grassini, Dora, Guarrera, Simonetta, Parlato, Caterina, Casorzo, Laura, Panero, Mara, Sarotto, Ivana, Giordano, Silvia, Cereda, Matteo, Montemurro, Filippo, Ponzone, Riccardo, Crosetto, Nicola, Naccarati, Alessio, Sapino, Anna, Marchiò, Caterina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426037/
https://www.ncbi.nlm.nih.gov/pubmed/36038884
http://dx.doi.org/10.1186/s13073-022-01104-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426037/
https://www.ncbi.nlm.nih.gov/pubmed/36038884
http://dx.doi.org/10.1186/s13073-022-01104-z

Ejemplares similares